Belapectin shows 49.3% reduction in new varices in MASH cirrhosis patients at EASL 2025

GALECTIN THERAPEUTICS INC

Belapectin 2 mg/kg reduced new varices by 49.3% vs placebo (p=0.04) in per-protocol population (n=287).
Only 4.3% of 2 mg/kg group had >10 kPa liver stiffness increase vs 12.5% placebo (p=0.02).
Safety profile comparable to placebo; no drug-related serious adverse events reported.
NAVIGATE trial: 355 patients randomized 1:1:1 to belapectin 2/4 mg/kg or placebo every other week for 18 months.
Data presented as late-breaking oral at EASL 2025 Congress on May 10, 2025 in Amsterdam.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.